Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE ImmunoCellular Therapeutics, Ltd.
LOS ANGELES, Jan. 13, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today provided an update on the Company's anticipated 2014 corporate strategies and milestones.
"2013 was an eventful year for ImmunoCellular Therapeutics," said Andrew Gengos, ImmunoCellular's Chief Executive Officer. "It was a year of progress, and some challenges – quite typical for a development-stage biotechnology company that is breaking new ground with a novel technology to treat cancer. As we enter 2014, we are focused on advancing our pipeline of cancer vaccines, and on creating and delivering value to all our stakeholders. We are committed to making the best data-driven decisions we can about how we move forward and invest our resources. We are confident that our clinical programs have meaningful therapeutic and commercial potential, and intend to ensure that our strategies are driven by appropriate medical and scientific rationales. We are also confident that we have more than enough resources to achieve our near-term goals and that we will continue our progress in building a leading cancer immunotherapy company and transforming the treatment of cancer."
ICT-107 Phase II Program
ImmunoCellular is committed to objectively assessing ICT-107's therapeutic value. The Company believes that ICT-107 has the potential to offer a meaningful difference for patients, and anticipates that the additional information to be gathered as analysis of the data from the phase II trial continues will reinforce that view.
The next steps for ICT-107 include the following:
ICT-121 and ICT-140 Programs
While advancing ICT-107 is ImmunoCellular's major focus in 2014, The Company also anticipates progress in its ICT-121 program in patients with recurrent GBM, being conducted at Cedars-Sinai Medical Center in Los Angeles, and in its ICT-140 program in patients with ovarian cancer.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles area-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized, the outcome and timing of our immunological data, the outcome of our end-of-phase II meeting with the FDA, EMA grant of orphan designation for ICT-107, our ability to show that PFS and OS outcomes are related with respect to ICT-107 in a manner that justifies further development and our ability to continue to our ICT-121 and ICT-104 programs successfully and in a timely manner. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
ImmunoCellular Therapeutics, Ltd.
©2012 PR Newswire. All Rights Reserved.
WISTV License Subsidiary, LCC
1111 Bull St.